Crystalys Therapeutics
Summary active Updated Jul 23, 2026This profile is AI-generated. If you spot an error, please help us fix it by sharing a URL to the correct information.
About
Crystalys Therapeutics is a clinical-stage biopharmaceutical company transforming the treatment of gout, headquartered in San Diego, California, and co-founded by Catalys Pacific and Novo Holdings 12. The company’s lead asset, dotinurad, was originally invented by Japan’s Fuji Yakuhin and is approved in Japan, China, Taiwan, the Philippines, and Thailand 12. Crystalys acquired global ex-Asia rights to dotinurad via a 2024 asset purchase from Urica Therapeutics 12.
Funding History
| Date | Round | Amount | Lead | Co-investors |
|---|---|---|---|---|
| 2026-07-22 | Series B | $130M | Frazier Life Sciences | Wellington Management, HBM Healthcare Investments, Soleus Capital, Cormorant Asset Management, Trails Edge Capital Partners, Pivotal bioVenture Partners, KCap Biotechnology Fund 123 |
The Series B follows a $205M Series A announced less than a year prior 12. Proceeds will fund global Phase 3 trials of dotinurad for gout and provide operational runway through clinical readouts and preparation for commercial launch 123.
What Investors Say
No independently sourced investor quotes found at time of publication.
What Founders Say
No independently sourced founder quotes found at time of publication.
Sources
-
BioSpace, “Crystalys Therapeutics Announces $130 Million Series B Financing to Advance Global Phase 3 Development and Commercialization of Dotinurad for Gout,” July 22, 2026. Accessed July 2026. https://www.biospace.com/press-releases/crystalys-therapeutics-announces-130-million-series-b-financing-to-advance-global-phase-3-development-and-commercialization-of-dotinurad-for-gout↩↩↩↩↩↩
-
Endpoints News, “Crystalys gets $130M to take Sobi-rivaling gout drug to market,” July 2026. Accessed July 2026. https://endpoints.news/crystalys-gets-130m-for-phase-3-tests-of-sobi-rivaling-gout-drug/↩↩↩↩↩↩
-
BioPharma Dive, “Crystalys nets $130M more to push gout drug through late-stage tests,” July 2026. Accessed July 2026. https://www.biopharmadive.com/news/crystalys-gout-dotinurad-series-b-venture-financing/825697/↩↩